奥氮平与利培酮治疗精神分裂症患者的效果和安全性  

Efficacy and Safety of Olanzapine and Risperidone in the Treatment of Cognitive Function in Schizophrenic Patients

作　　者：徐军 XU Jun(Jinzhou Kangning Hospital,Jinzhou 121000,China)

机构地区：[1]锦州市康宁医院,辽宁锦州121000

出　　处：《中国医药指南》2021年第32期99-100,103,共3页Guide of China Medicine

摘　　要：目的对比奥氮平与利培酮治疗精神分裂症患者的效果和安全性。方法将我院2018年3月至2019年3月收治的130例精神分裂症患者随机分为两组,每组65例,研究组患者采用奥氮平治疗,对照组患者使用利培酮治疗。治疗8周后,对两组患者的治疗效果、认知功能和不良反应进行对比。结果治疗前,两组PANSS各项评分比较,差异无统计学意义(P>0.05)。治疗后,两组患者的PANSS各项评分均优于治疗前(P<0.05)。两组连线测验情况比较,耗时和错误数差异无统计学意义(P>0.05)。治疗后,研究组CWT测试和WCST测验结果优于对照组(P<0.05)。研究组不良反应发生率为18.46%,低于对照组的40.00%(P<0.05)。结论奥氮平和利培酮治疗精神分裂症患者的效果确切,奥氮平的药物安全性和对患者认知功能的改善效果优于利培酮。Objective To compare the efficacy and safety of olanzapine and risperidone in the treatment of cognitive function in patients with schizophrenia.Methods From March 2018 to March 2019,130 schizophrenic patients admitted to our hospital were randomly divided into two groups,65 patients in each group.The study group were treated with olanzapine,and the control group were treated with risperidone.After 8 weeks of treatment,the therapeutic effect,cognitive function and adverse reactions of the two groups were compared.Results Before treatment,there was no significant difference in PANSS scores between the two groups(P>0.05).After treatment,the PANSS scores of both groups were better than those before treatment(P<0.05).There was no significant difference in the number of errors and time consuming between the two groups(P>0.05).After treatment,the CWT test and WCST test in the study group were better than those in the study group(P<0.05).The incidence of adverse reactions in the study group was 18.46%lower than 40.00%in the control group(P<0.05).Conclusion Olanzapine and risperidone are effective in the treatment of schizophrenia.Olanzapine is safer and better than risperidone in improving cognitive function.

关 键 词：精神分裂症 奥氮平 利培酮 认知功能 安全性 

分 类 号：R749.3[医药卫生—神经病学与精神病学]